source
- Parabilis Medicines raises $670 million in record-setting biotech IPO on NasdaqParabilis Medicines, a Cambridge, Massachusetts drug developer, completed its initial public offering on Nasdaq, raising $670 million. The offering is described as the largest biotech IPO in indus…
- AstraZeneca advances obesity pill to Phase 3 after mid-stage trials show ~11% weight lossAstraZeneca announced that its experimental oral GLP-1 drug, elecoglipron, will enter an extensive Phase 3 development program following encouraging data from two mid-stage studies in obesity and d…